Zobrazeno 1 - 10
of 245
pro vyhledávání: '"Philippe A, Cassier"'
Autor:
Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, Antoine Italiano
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors in advanced gastric cancer (AGC)
Externí odkaz:
https://doaj.org/article/092395fd8b914e7cbe0ceb717ec9a6b5
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIeramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination tr
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Allison Voisin, Maud Plaschka, Marlène Perrin-Niquet, Julie Twardowski, Insaf Boutemine, Baptiste Eluard, Guilhem Lalle, Pierre Stéphan, Khaled Bouherrou, Laurie Tonon, Roxane Pommier, Anthony Ferrari, Ulf Klein, Mélanie Wencker, Véronique Baud, Philippe A. Cassier, Yenkel Grinberg-Bleyer
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
CD8+ T cells are critical mediators of pathogen clearance and anti-tumor immunity. Although signaling pathways leading to the activation of NF-κB transcription factors have crucial functions in the regulation of immune responses, the CD8+ T cell-aut
Externí odkaz:
https://doaj.org/article/cb478953a89049eead0106dbe604bf78
Autor:
Vincent Ribrag, Julio C. Chavez, Carola Boccomini, Jason Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Ranjana Advani, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Iris Isufi, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Frank Shen, Sophie Michelliza, Harald Haeske, Kristen Hege, Michael Pourdehnad, John Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 139-153 (2022)
Abstract There is a need for additional treatment options for patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) who do not benefit from available therapies. We examined combinations of the cereblon E3 ligase modulator (CELM
Externí odkaz:
https://doaj.org/article/96c484da7911405ebd05aa9e00d581f2
Autor:
John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://doaj.org/article/2e9537a22ea94fefa65b2b3c6cd4e048
Autor:
Philippe A. Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101266- (2022)
Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gast
Externí odkaz:
https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700
Autor:
Fabrice Barlesi, Steven Kao, Philippe A Cassier, Hua Fang, Frances Fan, Kathryn Allaire, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associate
Externí odkaz:
https://doaj.org/article/20dbdf5be81c4b86b9fc3af9b764237c
Autor:
Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe A. Cassier, Kiyotaka Yoh, Antoine Italiano, Victor Moreno, Katriina Peltola, Takashi Seto, Ryo Toyozawa, Daniel E. Afar, Stefan Englert, Philip Komarnitsky, Stacie Lambert, Apurvasena Parikh, Gregory Vosganian, Bo Gao
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100405- (2021)
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://doaj.org/article/e1966145ff134f7d8b7360173186cc8e
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/7de98426096448a09b656dd2aaab8acf
Autor:
Anne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, Gwenaelle Garin, Jean-Noël Badel, David Kryza, Sylvie Chabaud, Laurence Gilles-Afchain, Gilles Clapisson, Claude Desuzinges, David Sarrut, Adrien Halty, Antoine Italiano, Masaharu Mori, Takuya Tsunoda, Toyomasa Katagiri, Yusuke Nakamura, Laurent Alberti, Claire Cropet, Simon Baconnier, Sandrine Berge-Montamat, David Pérol, Jean-Yves Blay
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with a dismal prognosis in advanced phases. We report a first-in-human phase I of monoclonal antibody (OTSA-101) targeting FZD10, overex
Externí odkaz:
https://doaj.org/article/f7e4c42b865f4a648c225b6c01e4f105